Aditya Birla Sun Life Pharma and Healthcare Fund

A Sectoral/Thematic Fund scheme from Aditya Birla Sun Life Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF209KB1O25).

NAV ₹41.2200 on 16 November 2026.

Expense ratio

Total expense ratio 1.07% a year for the Direct · Growth plan, as AMFI published it on 28 October 2026: base expense ratio 0.83%, brokerage 0.03%, transaction costs 0.00%, statutory levies including GST 0.21%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year19.1%12.8%-9.6%0.951.00
3 years20.8%13.0%-15.9%1.061.02
5 years15.5%13.0%-18.7%0.660.65

Too little NAV history for the 10-year figures.

Category rank: 8th of 13 Direct-Growth funds in Sectoral/Thematic Fund — Pharma, by 3-year Sortino ratio.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 99.4% of the portfolio.

  1. Torrent Pharmaceuticals Limited — 8.83%
  2. Sun Pharmaceutical Industries Limited — 8.35%
  3. Cipla Limited — 7.10%
  4. Apollo Hospitals Enterprise Limited — 6.60%
  5. Sai Life Sciences Limited — 4.54%
  6. Aurobindo Pharma Limited — 4.50%
  7. Ajanta Pharma Limited — 4.17%
  8. Dr. Lal Path Labs Ltd. — 3.90%
  9. Mankind Pharma Limited — 3.56%
  10. Emcure Pharmaceuticals Limited — 3.06%

Plans

Other funds in Sectoral/Thematic Fund

All 257 funds in Sectoral/Thematic Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.